Close menu

April 4th, 2022 | 12:19 CEST

Bayer, Cardiol Therapeutics, Formycon, NanoRepro: Top Biotech Stocks - Delivering!

  • Biotechnology
Photo credits:

Due to various public easing measures, the Corona pandemic is increasingly fading into the background. It has long been a hot ride for the stock market, especially for vaccine producers, but now investors are shifting their focus to other stocks in the biotech segment. After all, there are still many diseases that confront humanity with unresolved mysteries, and the field of human medical research seems endless. We focus on interesting stocks from the sector, which corrected strongly in the wake of the Ukraine downturn but are now trending north again. These trends are still in their infancy.

time to read: 4 minutes | Author: André Will-Laudien

Table of contents:

    Bayer - Leaving the past behind

    Bayer is back! The Company from Leverkusen seems to be slowly leaving the glyphosate crisis behind - now it is investing again. The Company is not spilling the beans but rather making big investments. With investments of around EUR 2 billion, Bayer wants to make its pharmaceuticals division fit for the future again in the next three years. According to management, the money will be spent on new technologies, automation and digitization. In the process, the strategic focus will be redefined. A significant portion of the funds will be used to expand biotechnology capacities, especially in cell and gene therapies, and expand the production site in Berkeley, California.

    Regardless, Germany will remain an important production site. More than EUR 1.4 billion will be invested in technologies, new production facilities and digitization projects at the pharmaceutical sites in Bergkamen, Berlin, Leverkusen, Weimar and Wuppertal. Following the highest loss in its company history in 2020, the agrochemicals and pharmaceuticals group returned to profitability last year, primarily with seeds and medicines. In view of the looming food crisis, Bayer should remain well-positioned. From a chart perspective, the breakout to the upside has begun between EUR 55.5 and EUR 58.5. Get in!

    Cardiol Therapeutics - The cardiovascular expert moves forward

    Cardiol Therapeutics Inc. (CRDL) is a biotechnology company focused on the discovery and clinical development of innovative anti-inflammatory therapies for the treatment of cardiovascular diseases. The share has been listed in Germany since March 2020 and had an exciting up and down year last year.

    CEO David Elsley is taking advantage of the increased attention on his Company to review its significant progress, saying, "In 2021, Cardiol Therapeutics achieved several important goals. We advanced new product development, key basic research initiatives and clinical programs focused on advancing the development of our pharmaceutical-grade cannabidiol formulations for use as an antifibrotic and anti-inflammatory therapy for cardiovascular disease." In total, the Company raised CAD 98 million and also completed a public offering on NASDAQ. Cardiol is now excellently positioned to develop new treatment options to improve patients' health and quality of life with heart disease. This important therapeutic area is currently still underrepresented in the medical world.

    In October 2021, Cardiol expanded the Lancer trial, approved initially to enroll patients at hospital centers in the United States under an FDA-approved IND, to include multiple hospital centers in Brazil and Mexico. The next milestone is now the completion of patient enrollment for the Phase II/III Lancer study. It is designed to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce severe cardiovascular and respiratory events in patients hospitalized with COVID-19 who have a history or risk factors for cardiovascular disease. Cardiol also believes it is in a good position to help people with acute myocarditis (heart muscle inflammation). Chronic heart failure affects 26 million people in the developed world. It remains a leading cause of death and hospitalization, with associated annual healthcare costs exceeding USD 30 billion in the United States alone.

    With the latest capital increase in 2021, Cardiol now has the opportunity to approach this billion-dollar heart disease market with the highest level of expertise. As of December 31, 2021, cash and cash equivalents totaled CAD 83.9 million. With 61.9 million shares, the Company is currently valued at CAD 112 million. The risk-reward ratio currently shows very clear opportunities on the buy-side!

    Formycon and NanoRepro - Delivering as promised

    We take another brief look at two protagonists from Germany. Here, too, some companies are making good progress with their pharmaceutical products and are repeatedly attracting the attention of investors.

    Munich-based biosimilar specialist Formycon is re-sorting itself in the Strüngmann universe. Their investment company Athos KG is currently Formycon's largest single shareholder with around 26.6%. Now it is about the biosimilar projects FYB201 and FYB202 from 2013 and 2017, which were previously developed in a collaboration. By reallocating company shares and integrating the long-standing partner Bioeq GmbH entirely, Formycon strengthens its competencies in several areas that are important for the development, approval and commercialization of biosimilars. At the same time, the attributable share of sales for Formycon increases. The Formycon share was valued at an expert-confirmed fair value of EUR 83.41 in the most recent investment transactions. It should be noted that the third biosimilar project (FYB206), which has not yet been announced, was also included in this valuation. The share rejoiced on this news, gaining 50% in just 3 weeks.

    NanoRepro recently reported 2021 numbers, and they were massively impacted by revenue around the COVID pandemic. The Company's revenue climbed from EUR 17 million to EUR 163 million, and operating profit was EUR 38.8 million, up from EUR 2.8 million. From the calculated earnings per share of EUR 2.30, EUR 0.50 is now to be distributed to shareholders. A forecast for 2022 was not provided after the Viromed due diligence was completed. The share price is currently bobbing listlessly back and forth between EUR 4.40 and EUR 5.20. NanoRepro had a strong year. Let's see how the cash is invested and how the pipeline develops.

    The biotech investment sector is highly volatile and strongly dependent on investor sentiment. In the current environment, the shares of Formycon and NanoRepro appear to be worth holding. However, more significant share price dynamics are only likely to be triggered by unexpectedly positive news. An investment in Bayer or Cardiol Therapeutics appears to be promising due to the good prospects.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
    In this respect, there is a concrete conflict of interest in the reporting on the companies.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
    For this reason, there is also a concrete conflict of interest.
    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author

    Related comments:

    Commented by Juliane Zielonka on December 8th, 2023 | 07:20 CET

    Which stocks are leading the fight against cancer and chronic diseases? Defence Therapeutics, Merck and BioNTech

    • Biotechnology
    • Pharma

    The pharmaceutical industry is facing complex developments in the fight against cancer, with Defence Therapeutics making significant progress with the successful FDA filing for its drug for the targeted treatment of tumors. The growing market opportunities in oncology until 2032 underline the potential of this breakthrough. In contrast, Merck KGaA is experiencing a severe setback with an 11% share price decline following the failure of evobrutinib for the relief of MS in late-stage clinical trials. According to analysts, this also impacts the Company's valuation. Despite promising cancer-fighting approaches, BioNTech faces uncertainties due to a reduced revenue forecast for 2023 and an 'Underweight' rating from JP Morgan. Despite these challenges, the sector remains dynamic. Find out which shares could be worthwhile in the long term here.


    Commented by Juliane Zielonka on December 7th, 2023 | 07:00 CET

    New developments in the healthcare market: Cardiol Therapeutics, Amazon and Bayer shares in focus

    • Biotechnology
    • Pharma
    • Healthcare

    Cardiol Therapeutics, a clinical-stage life sciences company focusing on therapies for heart inflammation, has secured a renowned clinic to advance its Phase II MAvERIC-Pilot study. This study, focused on combating recurrent pericarditis, promises to provide sound approaches to improve the quality of life of affected patients. Amazon has been dabbling in the healthcare sector since 2015 and is gradually conquering the telemedicine market. The path to telemedicine for Prime members, through the acquisition of companies such as "One Medical" and "PillPack", poses challenges. In contrast, Bayer is once again caught in the crossfire of legal disputes. The recent glyphosate trial loss before a jury in Philadelphia calls for a strategic realignment. At the same time, Bayer is attempting to provide new impetus in the area of women's health through a partnership in the field of hormonal contraception. Find out which development holds promise here.


    Commented by Fabian Lorenz on November 30th, 2023 | 07:10 CET

    Biotech Alert! Morphosys, Bayer, BioNTech and Defence Therapeutics

    • Biotechnology
    • Pharma

    Morphosys is not for the faint-hearted. After unclear study results, the stock gave up its annual gains within a few days. Analysts are also divided on what the future holds. On December 10, the study details will be released, hopefully shedding light on the situation. Bayer shareholders are currently seeing dark clouds. The stock plummeted from EUR 40 to EUR 30 in a short time. Is the dividend now at risk, or is the entire company in jeopardy? There is a slew of positive news for Defence Therapeutics. Can the stock break out of its sideways trend? A potential partner for the Canadians could be BioNTech. The German biotech favourite is working with full coffers on cancer vaccines. However, analysts remain cautious.